Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy

Open Access

Peer-reviewed

Research Article

Robert C. Jackson,

Affiliation Pharmacometrics Ltd, Cambridge, United Kingdom
⨯
Giovanni Y. Di Veroli ,

* E-mail: Giovanni.DiVeroli@astrazeneca.com

Affiliations Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, QCP, Early Clinical Development—Innovative Medicines, AstraZeneca, Cambridge, United Kingdom

http://orcid.org/0000-0002-5251-8181

⨯
Siang-Boon Koh,

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
⨯
Ian Goldlust,

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
⨯
Frances M. Richards,

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
⨯
Duncan I. Jodrell

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
⨯

Reader Comments (0)

Cell cycle and cell division
Is the Subject Area "Cell cycle and cell division" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Synthesis phase
Is the Subject Area "Synthesis phase" applicable to this article?

Thanks for your feedback.
Protein kinases
Is the Subject Area "Protein kinases" applicable to this article?

Thanks for your feedback.
Cyclins
Is the Subject Area "Cyclins" applicable to this article?

Thanks for your feedback.